MTSR Metsera, Inc.

Nasdaq metsera.com


$ 61.91 $ -0.69 (-1.08 %)    

Friday, 31-Oct-2025 19:31:04 EDT
QQQ $ 629.11 $ 3.02 (0.48 %)
DIA $ 475.58 $ 0.66 (0.14 %)
SPY $ 682.10 $ 2.23 (0.33 %)
TLT $ 90.09 $ -0.27 (-0.3 %)
GLD $ 368.20 $ -2.01 (-0.54 %)
$ 63.04
$ 64.00
$ 61.58 x 1
$ 64.19 x 1
$ 62.48 - $ 64.33
$ 12.30 - $ 66.10
5,924,684
na
6.61B
$ 2.46
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 07-28-2025 06-30-2025 10-Q
2 05-12-2025 03-31-2025 10-Q
3 03-26-2025 12-31-2024 10-K
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

Core News & Articles

Pfizer Inc. today announced that it has filed a lawsuit against Metsera, Inc., its Board of Directors, and Novo Nordisk, S.A. i...

Core News & Articles

Pfizer Inc. (NYSE:PFE) today announced the U.S. Federal Trade Commission has granted early termination of the waiting period un...

Core News & Articles

https://www.semafor.com/article/10/30/2025/pfizer-mulls-suing-metsera-novo-over-topping-bid

 pfizer-blasts-novo-nordisks-9-billion-counteroffer-for-metsera-as-reckless

Novo Nordisk's $9 billion offer for Metsera challenges Pfizer's existing merger deal, prompting sharp criticism and pot...

Core News & Articles

- Reuters 

Core News & Articles

Pfizer Inc. (NYSE:PFE) is aware of the reckless and unprecedented proposal by Novo Nordisk A/S (NYSE:NVO) to acquire Metsera, I...

 metsera-reports-up-to-14-weight-loss-in-phase-2b-obesity-trial

Metsera's MET-097i cut weight up to 14% in Phase 2b trials, with manageable side effects, as the company targets a global P...

Core News & Articles

Placebo-subtracted mean weight loss up to 14.1% after 28 weeks with no plateauPotential for best-in-class tolerability with min...

Core News & Articles

Leerink Partners analyst David Risinger downgrades Metsera (NASDAQ:MTSR) from Outperform to Market Perform and lowers the pr...

 pfizer-tries-to-revitalize-obesity-portfolio-with-5-billion-matsera-deal

Pfizer will buy Metsera for $4.9 billion plus milestone payments, adding incretin, amylin, and oral obesity drug candidates to ...

Core News & Articles

- Reuters Cites Conf Call

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION